JelloX Biotech Inc., a leading innovator in the pathology field, has announced a collaboration with Mayo Clinic through a know-how agreement. The partnership aims to further develop and validate JelloX’s 3D digital imaging and AI analysis technology for precision cancer diagnosis. This collaboration follows JelloX’s participation in the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator program.
JelloX’s 3D pathology imaging technology, coupled with artificial intelligence, offers enhanced spatial analysis capabilities that can support accurate and consistent cancer diagnosis. Unlike traditional 2D imaging methods, which may miss critical tumor biomarkers and suffer from interpretive variability, JelloX’s 3D imaging technology provides a comprehensive view of tissue architecture. This advancement is expected to improve diagnostic accuracy and provide pathologists with a more precise diagnosis for cancer patients.
Moreover, JelloX’s technology allows the same biopsy tissue to be analyzed through genomic sequencing and proteomics, enabling a full spectrum of precision medicine for patients. The collaboration with Mayo Clinic through the know-how agreement and MedTech Accelerator program has been a significant milestone for JelloX, as it strives to bring its 3D pathology technology to research and clinical practice.
Dr. Yen-Yin Lin, CEO and founder of JelloX, expressed excitement about the collaboration, stating that their goal is to provide researchers and clinicians with more precise diagnostic tools and support pharmaceutical companies in developing targeted treatments for patients.
This collaboration exemplifies the power of innovation and collaboration in advancing healthcare outcomes. As the field of pathology continues to evolve, the integration of digital solutions like JelloX’s 3D pathology imaging technology holds great potential for the future of medical diagnostics and treatment.
It is important to note that Mayo Clinic has a financial interest in the technology mentioned in this press release. Any revenue generated will be used to support Mayo Clinic’s not-for-profit mission in patient care, education, and research.
For more information about JelloX and its 3D digital pathology solution, please visit their website at [ JelloX Website ].
Contact:
JelloX Biotech Inc.
Tel: +886-3-6583058
Fax: +886-3-5620853
Email: [email protected]